ATAI Life Sciences BV

#115 in public ATAI.US public

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

https://newhedge.io/api/v2/companies/atai-life-sciences-bv/bitcoin-acquisitions

API Documentation

API Access Required

API access is available with our Advanced plan.

Bitcoin Holdings

Total Bitcoin ₿ 58 BTC

% of 21M Supply 0.0%

Current Value $3,659,008

Cost Basis $5,000,000

ROI -26.82%

% of Company 0.2%

mNAV

459.23x

BTC/Share ₿ 0.00000036 BTC

Market Cap $1,910,785,152

Enterprise Value $1,911,095,152

Latest Purchase Mar 31, 2025

Avg. cost / BTC $86,207

ATAI Life Sciences BV Stock Priced in BTC

0.000084 BTC

ATAI Life Sciences BV Bitcoin Holdings Over Time

₿ 58 BTC

Bitcoin Acquisitions History

Type	BTC Change	Holdings	Transaction Value	Date
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Get instant access to full data Register for free

Financial Highlights

Revenue (TTM) $3,488,000

Profit Margin 0%

Operating Margin -3239.1%

ROE -378.0%

Analyst Rating 100% Buy (7 analysts)

Target Price $14

ROA -33.34%

EPS $-2.84

Book Value $0.543

Target Price $14

Current Volume 11,326,200

Avg Volume (30d) 7,976,760

Volume vs Avg 1.42x

ATAI Life Sciences BV Stock Price vs Bitcoin

$5.19 / $63,086

Company Overview

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Sector Healthcare

Industry Biotechnology

Sub-Industry Biotechnology

Employees 99

Exchange NASDAQ

Fiscal Year End December

IPO Date June 2021

Website Visit Website

Stock Returns

Share Price $5.19

1W Return +13.32%

1M Return +7.9%

3M Return +40.27%

1Y Return +91.51%

1Y vs BTC +135.0%

52W High $6.75

% Down from 52W High -23.1%

Key Executives

Mr. Christian Angermayer Co-Founder & Chairman of the Board

Age: 48

Dr. Srinivas G. Rao M.D., Ph.D. Co-Founder, CEO & Executive Director

Age: 57

Dr. Gerd G. Kochendoerfer Ph.D. Chief Operating Officer

Age: 58

Mr. Ryan Barrett J.D. Chief Legal & Business Officer

Age: 45

Mr. Michael Eric Faerm Chief Financial Officer

Age: 59

Ms. Anne Johnson CPA Chief Accounting Officer

Age: 57

Dr. Glenn Short Ph.D. Chief Scientific Officer

Age: 56

Dr. Jason Awe Ph.D. Vice President of Investor Relations

Age: 2026

Company Details

Address 250 West 34th Street, New York, NY, United States, 10119

Phone 332 282 0507

ISIN NL0015000DX5

CIK 0001840904

Currency USD

Most Recent Quarter 2026-03-31

Growth Metrics

Earnings Growth (YoY) -96.8%

Revenue Growth (YoY) -38.7%

Balance Sheet (Q1 2026)

Total Assets $264,877,000

Total Liabilities $66,098,000

Total Equity $198,683,000

Cash & Equivalents $0

Total Debt $310,000

Current Assets $250,066,000

Current Liabilities $24,964,000

Long-term Debt $0

Additional Financials

EBITDA -$121,896,000

Gross Profit -$54,607,000

Revenue per Share $0.013

Diluted EPS (TTM) $-2.84

Outstanding Shares 160,000,000

EPS Estimates

Current Quarter $-0.1119

Current Year $-0.44

Next Quarter $-0.1032

Next Year $-0.4551

Recent Insider Activity

Name	Title	Type	Shares	Price	Value	Date	SEC
Kevin James Craig	INSIDER	Sell	42,579	$5.00	$212,895	Apr 20, 2026
Get instant access to full data Register for free

Major Holders

Major Institutional Holders

Deep Track Capital, LP

3.2594%

5,215,040 shares

Vanguard Capital Management, LLC

3.1946%

5,111,360 shares

UBS Group AG

2.0173%

3,227,680 shares

BlackRock Inc

1.8566%

2,970,560 shares

Adage Capital Partners Gp LLC

1.5327%

2,452,320 shares

Susquehanna International Group, LLP

1.4359%

2,297,440 shares

Millennium Management LLC

1.1854%

1,896,640 shares

Morgan Stanley - Brokerage Accounts

1.0465%

1,674,400 shares

Candriam Luxembourg S.C.A.

0.8383%

1,341,280 shares

Qube Research & Technologies

0.7855%

1,256,800 shares

Major Mutual Fund Holders

Vanguard Total Stock Mkt Idx Inv

2.5367%

4,058,720 shares

ARK Genomic Revolution

1.1223%

1,795,680 shares

ARK Genomic Revolution ETF

1.0905%

1,744,800 shares

Vanguard Institutional Extnd Mkt Idx Tr

0.5898%

943,680 shares

iShares Biotechnology ETF

0.5857%

937,120 shares

Candriam Eqs L Biotech C USD Cap

0.469%

750,400 shares

HBM Healthcare Investments AG Ord

0.4088%

654,080 shares

First Trust Small Cap Gr AlphaDEX® ETF

0.2803%

448,480 shares

Fidelity Extended Market Index

0.2789%

446,240 shares

Schwab US Small-Cap ETF™

0.2558%

409,280 shares

Frequently Asked Questions

Common questions about ATAI Life Sciences BV's Bitcoin holdings

How much Bitcoin does ATAI Life Sciences BV hold?

ATAI Life Sciences BV currently holds 58 BTC, which represents 0.0% of the total Bitcoin supply (21 million). This makes them the 115th largest public Bitcoin holder.

What is the current value of ATAI Life Sciences BV's Bitcoin holdings?

As of today, ATAI Life Sciences BV's Bitcoin holdings are worth approximately $3,659,008. This represents 0.2% of the company's total market value.

What is ATAI Life Sciences BV's average cost basis for Bitcoin?

ATAI Life Sciences BV's average cost basis for their Bitcoin purchases is $5,000,000 per Bitcoin. Their current return on investment (ROI) is -26.82%.

When did ATAI Life Sciences BV last buy Bitcoin?

ATAI Life Sciences BV's most recent Bitcoin purchase was Mar 31, 2025. View purchase details

What type of company is ATAI Life Sciences BV?

ATAI Life Sciences BV is a public company in the Healthcare sector and Biotechnology industry with approximately 99 employees .

What is ATAI Life Sciences BV's market capitalization?

ATAI Life Sciences BV has a market capitalization of approximately $1,910,785,152 and annual revenue of $3,488,000 .

What is ATAI Life Sciences BV's mNAV?

ATAI Life Sciences BV's mNAV (Market-to-Net Asset Value) is 459.23x, comparing the company's market value to its Bitcoin holdings value. An mNAV of 1.0 means market value equals Bitcoin stash, while >1.0 indicates a premium for the company's Bitcoin strategy.

What is ATAI Life Sciences BV's market cap and enterprise value?

ATAI Life Sciences BV has a market capitalization of $1,910,785,152 and an enterprise value of $1,911,095,152. Enterprise value represents the total company value including debt and cash, providing a more complete valuation picture than market cap alone.